2022-01-06
Expanded global scientific and medical leadership role
Veracyte announced Kennedy’s expanded Global Chief Scientific Officer and Chief Medical Officer role.
View the source03 / 04 · Scientific & medical leadership
Science into clinical questions
Scientific and medical leadership connected genomic classifiers to questions in thyroid and pulmonary diagnostics.
← Back to the career genomeA sourced chapter
The work in context.
Kennedy served as Chief Scientific Officer from September 2008 and became Chief Medical Officer in January 2018. Her expanded Global CSO/CMO role was announced in January 2022. Veracyte reported an agreed departure effective December 31, 2022. Selected coauthored publications document work on molecular classifiers; they should not be read as claims of sole authorship or a quantified personal clinical outcome.
How could genomic classifiers help frame clinical questions across more than one disease area?
Documented milestones, not claimed outcomes
On the record.
Research linked to this period
Connected questions.
Thyroid diagnostics
Molecular classification of thyroid nodules and expressed genomic signals.
Explore the areaPulmonary risk & interstitial disease
Genomic classifiers studied in usual interstitial pneumonia and lung-cancer risk assessment.
Explore the areaTranscriptomics & classification
RNA-sequencing and machine-learning methods used to investigate diagnostic questions.
Explore the areaSelected coauthored work
Published evidence.
2010
2015
2017
2021
2022
2022
Maximizing Small Biopsy Patient Samples: Unified RNA-Seq Platform Assessment of over 120,000 Patient Biopsies
Context: Published online in December 2022; journal issue citation is 2023.
Related records, carefully described
Beyond the papers.
US10446272B2
Methods and compositions for classification of samples. An example issued patent record; no assertion about current enforceability or family count.
View patent record ↗Precision Medicine World Conference presentation announced
Large-scale genomic data and machine learning in diagnostic development. announced, delivery not independently confirmed.
View announcement ↗What the evidence can say
The boundary matters.
Coauthorship and executive roles do not establish sole authorship, individual invention or a quantified personal patient outcome. The documented Veracyte departure was effective December 31, 2022.
Documented relationships
People & institutions on record
A line here means a recorded role, training or publication affiliation. It does not infer a permanent team or employment from coauthorship.
- Executive roleGiulia C. KennedyVeracyte
Chief Scientific Officer; Chief Medical Officer from 2018; Global CSO/CMO in 2022
View record
Chapter sources
Evidence is linked to its original record. Dates and interpretations are qualified in the chapter text.
- Veracyte 2022 definitive proxy statement U.S. SEC / Veracyte · 2022-04-26
- Veracyte announces key leadership promotions Veracyte · 2022-01-06
- Veracyte Form 8-K: departure of certain officer U.S. SEC / Veracyte · 2022-12-14
- Molecular classification of thyroid nodules PubMed / NLM · 2010
- Classification of usual interstitial pneumonia PubMed / NLM · 2015
- Analytical performance of Envisia PubMed / NLM · 2017
- Analytical validation of the Percepta genomic sequencing classifier PubMed / NLM · 2021
- Clinical validation and utility of Percepta GSC PubMed / NLM · 2022
- Unified RNA-Seq platform assessment PubMed / NLM · 2022-12-22